Premium
Determinants of Mortality Among Postmenopausal Women in the Women's Health Initiative Who Report Rheumatoid Arthritis
Author(s) -
Kuller Lewis H.,
Mackey Rachel H.,
Walitt Brian T.,
Deane Kevin D.,
Holers V. Michael,
Robinson William H.,
Sokolove Jeremy,
Chang Yuefang,
Liu Simin,
Parks Christine G.,
Wright Nicole C.,
Moreland Larry W.
Publication year - 2014
Publication title -
arthritis and rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.106
H-Index - 314
eISSN - 2326-5205
pISSN - 2326-5191
DOI - 10.1002/art.38268
Subject(s) - medicine , rheumatoid arthritis , rheumatoid factor , women's health initiative , proportional hazards model , postmenopausal women
Objective Rheumatoid arthritis (RA) patients have an increased risk of cardiovascular disease (CVD) and mortality. We measured anti–cyclic citrullinated peptide (anti‐CCP) antibody levels and determined use of disease‐modifying antirheumatic drugs (DMARDs) among women in the Women's Health Initiative (WHI). Using these data, we undertook this study to assess total mortality over 10 years of followup among white, black, or Hispanic women with self‐reported RA in the WHI. Methods Using stored baseline serum, we measured anti‐CCP, rheumatoid factor (RF), and antinuclear antibodies (ANAs) in 9,988 women who reported having RA. Based on a previous chart review study, probable RA was defined as either self‐reported RA and anti‐CCP positivity, or anti‐CCP negativity and DMARD use. Cox proportional hazards regression was used to model the relationship of self‐reported RA, DMARD exposure, and anti‐CCP positivity to total mortality, using followup data through April 2009. Results At baseline, the mean age was 62.8 years; 24.5% of subjects were black and 10% were Hispanic. Prevalence of anti‐CCP positivity was 8.1% (n = 812), and 217 women were anti‐CCP negative but had reported use of DMARDs; therefore, 1,029 women (of 9,988) were classified as having probable RA, and 8,958 were classified as unlikely to have RA (with data on DMARD use missing for 1 subject). Age‐adjusted mortality rates were ∼2‐fold higher for anti‐CCP–positive women, with 20.2 deaths per 1,000 person‐years, as compared to 11.4 deaths per 1,000 person‐years among anti‐CCP–negative women with self‐reported RA who never used DMARDs. Among women who did not report any arthritis at baseline, we found 8.3 deaths per 1,000 person‐years. The increased risk among anti‐CCP–positive women with RA was not explained by age, RF positivity, ANA positivity, or DMARD use. Conclusion Anti‐CCP–positive RA was associated with substantial excess mortality among postmenopausal women in the WHI. This result was not explained by the risk factors we measured.